Large-scale collaboration will leverage each institution’s expertise and infrastructure to advance understanding of the biological basis of pediatric cancers, identify new vulnerabilities of these diseases and accelerate cures globally
Scientists have solved the structure of an important complex of RAS-pathway proteins, explaining how known mutations lead to disease and suggesting potential new binding sites for cancer drugs.
Through the Broad’s Cancer Dependency Map, researchers are searching for genetic vulnerabilities in cancer cells that could lead the way to better precision drugs.
Cancer cells that cannot repair a certain form of DNA mutation become strongly dependent on single enzyme to survive, creating a new potential opportunity for drug development.